5 completed, 1 terminated, 1 unknown. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Keratoconjunctivitis: new trials by email Literature Review of Keratoconjunctivitis trials Research Report on Keratoconjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B punctum plug insertion, Eye Drops, Lubricant - Dry Eye, Keratoconjunctivitis Sicca | Phase 1 | Unknown | Eximore Ltd. | 20 | 2022-09-29 | 2023-09-07 |
| Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease INV-102, Vehicle - Dry Eye Disease | Phase 1 / Phase 2 | Completed | Invirsa, Inc. | 84 | 2022-08-30 | 2026-09-18 |
| Topical rVA576 for Treatment of Atopic Keratoconjunctivitis rVA576, Placebo - Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal | Phase 1 / Phase 2 | Terminated | AKARI Therapeutics | 12 | 2019-03-04 | 2025-04-10 |
| A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers PP-001, Placebo - Keratoconjunctivitis, Ocular Surface Disease | Phase 1 | Completed | Panoptes Pharma GmbH | 45 | 2018-11-20 | 2024-01-12 |
| Safety and Efficacy of PG101 for Dry Eye Syndrome PG101 - Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Rhodes Pharmaceuticals, L.P. | 72 | 2013-12-01 | 2014-03-05 |
| A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0% - Keratoconjunctivitis Sicca | Phase 1 | Completed | Rigel Pharmaceuticals | 36 | 2012-11-01 | 2014-08-04 |
| A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) voclosporin ophthalmic solution - Keratoconjunctivitis Sicca | Phase 1 | Completed | Lux Biosciences, Inc. | 35 | 2009-02-01 | 2012-06-22 |
Keratoconjunctivitis Sicca (5) · Dry Eye Syndromes (3) · Conjunctivitis, Allergic (1)
Conjunctival Diseases (7) · Conjunctivitis (7) · Corneal Diseases (7) · Eye Diseases (7) · Keratitis (7) · Lacrimal Apparatus Diseases (5) · Dry Eye Syndromes (2) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1)
Gels (1) · Lubricant Eye Drops (1)
AKARI Therapeutics (1) · Eximore Ltd. (1) · Invirsa, Inc. (1) · Lux Biosciences, Inc. (1) · Panoptes Pharma GmbH (1) · Rhodes Pharmaceuticals, L.P. (1) · Rigel Pharmaceuticals (1)
United States (4) · Austria (1) · Mexico (1) · Spain (1) · United Kingdom (1)
Gail Torkildsen, M.D. (1) · Gail Torkildsen, MD (1) · Nallely Ramos Betancourt, Dr. (1) · Robert Shalwitz, MD (1) · Sajjad Ahmad (1)
PMID 15948994, PMID 16021174, PMID 17054241, PMID 22511024, PMID 24695688, PMID 26783543